Avagacestat
| CAS No. | 1146699-66-2 | Cat. No. | BCP01770 |
| Name | Avagacestat | ||
| Synonyms | BMS-708163;BMS708163;BMS 708163; | ||
| Formula | C20H17ClF4N4O4S | M. Wt | 520.89 |
| Description | Avagacestat, also known as BMS-708163, is an oral GSI designed for selective inhibition of Aβ synthesis currently in development for the treatment of mild to moderate and predementia AD. In addition to the desired effect on Aβ synthesis, GSIs affect Notch processing, which is thought to mediate some toxic adverse effects reported with this drug class. | ||
| Pathways | Protease/Metabolic Enzyme Neuro Signaling Pathway Wnt/Stem Cell | ||
| Targets | Gamma secretase Notch | ||
Structure
Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.
For product details of different batches, please contact our Customer
- Service & Tech Support:orders@biochempartner.com
- Website:www.biochempartner.com
Products are for research use only and not for human use. We do not sell to patients.